IRVINE, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Helio Genomics ("Helio" or "the Company"), an AI-driven healthcare company specializing in diagnostics technology and test development for cancer detection, today announced acceptance of a late-breaking oral presentation at the European Association for the Study of the Liver (EASL) Congress, which takes place June 5-8, 2024 in Milan, Italy. EASL is the largest professional body in Europe devoted to liver health. Dr. Richard Van Etten, Helio's Chief Medical Advisor, will present data from the Company's pivotal Clinical Trial Multi-analyte Blood Test (CLiMB) study on Saturday, June 8 at 3:15 PM CET.
CLiMB is a multi-site, prospective study comparing the sensitivity and specificity of Helio's HelioLiver multi-analyte blood test to ultrasound for ...
Full story available on Benzinga.com
https://Benzinga.com